Advertisement AMDL closes private offering - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

AMDL closes private offering

Theranostics company AMDL has conducted the closing of its combined Regulation D/Regulation S private unit offering of two million shares of common stock and warrants to purchase one million shares of common stock, generating net proceeds of approximately $5.43 million.

The shares of AMDL common stock were sold at $3.09 per share and the four-year warrants included in the units are exercisable at $4.74 per share. Warrants to purchase an additional 200,751 shares were issued to AMDL’s placement agents at the same exercise price.

Gary Dreher, president of AMDL, said: “The reception to the offering was gratifying under the current economic climate. These funds provide some of the additional working capital we need to expand Jade Pharmaceutical’s new business opportunities and product development efforts in China and for our other general working capital needs.”